F-351の市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

ヒドロニドン（F-351）は、GNIの完全子会社であるShanghai Genomicsが開発した非ステロイド性抗炎症薬（NSAID）です。ヒドロニドンは肝星状細胞の増殖を抑制し、TGF-Bシグナル伝達経路も阻害します。Shanghai GenomicsはF-351を慢性肝炎（HBV）による肝線維症の治療薬として開発しています。さらなる適応症として、F-351は非アルコール性脂肪性肝炎（NASH）肝疾患、非アルコール性脂肪性肝疾患（NAFLD）、慢性腎不全の治療薬として開発される可能性があります。

現在、B型慢性肝炎の肝線維症に対するヒドロニドンの有効性と安全性を確認するため、フェーズ3試験（NCT05115942）で評価されています。試験は2024年6月までに完了する予定です。

当レポートでは、中国のB型慢性肝炎向けF-351について調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 B型慢性肝炎におけるF-351の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 F-351市場の評価

• B型慢性肝炎におけるF-351の市場見通し
• 中国の分析
  • 中国のB型慢性肝炎向けF-351の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: F-351, Clinical Trial Description, 2023
• Table 2: F-351, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: F-351 Market Size in China, in USD million (2019-2032)

List of Figures

• Figure 1: F-351 Market Size in China, USD million (2019-2032)

"F-351 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about F-351 for chronic hepatitis B in China. A detailed picture of the F-351 for chronic hepatitis B in China for the study period 2019 -2032 is provided in this report along with a detailed description of the F-351 for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the F-351 market forecast analysis for chronic hepatitis B in China, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.

Drug Summary:

Hydronidone (F-351) is a nonsteroidal anti-inflammatory drug (NSAID) developed by Shanghai Genomics, a wholly owned subsidiary of GNI. It inhibits hepatic stellate cell proliferation and also the TGF-B signaling pathway. Shanghai Genomics is developing F-351 to treat liver fibrosis induced by chronic hepatitis (HBV). For additional indications, F-351 has the potential to be further developed for Non-alcoholic steatohepatitis (NASH) liver disease, Non-alcoholic fatty liver disease (NAFLD), and chronic kidney failure.

Currently, the drug is being evaluated in a Phase III (NCT05115942) trial to confirm the efficacy and safety of hydronidone in treating chronic hepatitis B liver fibrosis. The trial is anticipated to be complete by June 2024.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the F-351 description, mechanism of action, dosage and administration, research and development activities in chronic hepatitis B.
• Elaborated details on F-351 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the F-351 research and development activities in chronic hepatitis B across China.
• The report also covers the patents information with expiry timeline around F-351.
• The report contains forecasted sales of F-351 for chronic hepatitis B till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic hepatitis B.
• The report also features the SWOT analysis with analyst views for F-351 in chronic hepatitis B.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

F-351 Analytical Perspective by DelveInsight

• In-depth F-351 Market Assessment

This report provides a detailed market assessment of F-351 for chronic hepatitis B in China. This segment of the report provides forecasted sales data from 2024 to 2032.

• F-351 Clinical Assessment

The report provides the clinical trials information of F-351 for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for chronic hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence F-351 dominance.
• Other emerging products for chronic hepatitis B are expected to give tough market competition to F-351 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of F-351 in chronic hepatitis B.
• Our in-depth analysis of the forecasted sales data of F-351 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the F-351 in chronic hepatitis B.

Key Questions:

• What is the product type, route of administration and mechanism of action of F-351?
• What is the clinical trial status of the study related to F-351 in chronic hepatitis B and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the F-351 development?
• What are the key designations that have been granted to F-351 for chronic hepatitis B?
• What is the forecasted market scenario of F-351 for chronic hepatitis B?
• What are the forecasted sales of F-351 in China?
• What are the other emerging products available and how are these giving competition to F-351 for chronic hepatitis B?
• Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?

Table of Contents

1. Report Introduction

2. F-351 Overview in Chronic hepatitis B

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. F-351 Market Assessment

• 5.1. Market Outlook of F-351 in Chronic hepatitis B
• 5.2. China Analysis
  • 5.2.1. Market Size of F-351 in China for Chronic hepatitis B

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options